"nonacneiform" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "non",
        "3": "acneiform"
      },
      "expansion": "non- + acneiform",
      "name": "prefix"
    }
  ],
  "etymology_text": "non- + acneiform",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "nonacneiform (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms prefixed with non-",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "1916 March, Albert Strickler, John A. Kolmer, Jay F. Schamberg, “Complement Fixation in Acne vulgaris”, in Journal of Cutaneous Diseases",
          "text": "Not only were acne cases tested, but also the blood in various nonacneiform skin diseases, and also patients without any skin affection.",
          "type": "quotation"
        },
        {
          "ref": "2017, Giuseppe Tridente, Adverse Events and Oncotargeted Kinase Inhibitors, page 338",
          "text": "Most common events across all dosing regimens included diarrhea (64%), nonacneiform rash (60%), liver enzyme abnormalities (50%), fatigue (48%), nausea (45%), and photosensitivity (40%).",
          "type": "quotation"
        },
        {
          "ref": "2019 October, Anna G. Mackin, Paua E. Pecen, Amanda L. Dinsmore, Jennifer L. Patnaik, Rene Gonzalez, William A. Robinson, Alan G. Palestine, “Inflammatory side effects of BRAF and MEK inhibitors”, in Melanoma Research, volume 29, number 5",
          "text": "The most common inflammatory side effects for the entire cohort included arthralgias/myalgias (32.9%), nonacneiform rash (28.0%), pyrexia (25.5%), and erythema nodosum (11.2%), although side effects differed across the class of therapy.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "Not acneform; unlike acne."
      ],
      "id": "en-nonacneiform-en-adj-5WCImOWP",
      "links": [
        [
          "acneform",
          "acneform"
        ],
        [
          "unlike",
          "unlike"
        ],
        [
          "acne",
          "acne"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "nonacneiform"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "non",
        "3": "acneiform"
      },
      "expansion": "non- + acneiform",
      "name": "prefix"
    }
  ],
  "etymology_text": "non- + acneiform",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "nonacneiform (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        "English adjectives",
        "English entries with incorrect language header",
        "English lemmas",
        "English terms prefixed with non-",
        "English terms with quotations",
        "English uncomparable adjectives"
      ],
      "examples": [
        {
          "ref": "1916 March, Albert Strickler, John A. Kolmer, Jay F. Schamberg, “Complement Fixation in Acne vulgaris”, in Journal of Cutaneous Diseases",
          "text": "Not only were acne cases tested, but also the blood in various nonacneiform skin diseases, and also patients without any skin affection.",
          "type": "quotation"
        },
        {
          "ref": "2017, Giuseppe Tridente, Adverse Events and Oncotargeted Kinase Inhibitors, page 338",
          "text": "Most common events across all dosing regimens included diarrhea (64%), nonacneiform rash (60%), liver enzyme abnormalities (50%), fatigue (48%), nausea (45%), and photosensitivity (40%).",
          "type": "quotation"
        },
        {
          "ref": "2019 October, Anna G. Mackin, Paua E. Pecen, Amanda L. Dinsmore, Jennifer L. Patnaik, Rene Gonzalez, William A. Robinson, Alan G. Palestine, “Inflammatory side effects of BRAF and MEK inhibitors”, in Melanoma Research, volume 29, number 5",
          "text": "The most common inflammatory side effects for the entire cohort included arthralgias/myalgias (32.9%), nonacneiform rash (28.0%), pyrexia (25.5%), and erythema nodosum (11.2%), although side effects differed across the class of therapy.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "Not acneform; unlike acne."
      ],
      "links": [
        [
          "acneform",
          "acneform"
        ],
        [
          "unlike",
          "unlike"
        ],
        [
          "acne",
          "acne"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "nonacneiform"
}